GlassScriptPhysician profile
Flavia Marrero Nelson
NPI 1891722518
$263,535.16
in general payments reported to CMS, 2019-2025
18 companies · $26K in 2025
The $26K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $73K · 2021: $22K · 2022: $34K · 2023: $36K · 2024: $9,887 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $34K · Travel and Lodging: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $9,138 · Honoraria: $3,850 · Education: $41.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $34,340.00 |
| Travel and Lodging | $13,857.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,296.00 |
| Food and Beverage | $9,137.53 |
| Honoraria | $3,850.00 |
| Education | $41.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $59,822.25 | 2019-2025 | Zeposia |
| Sanofi US Services INC. | $58,200.00 | 2020 | |
| Genzyme Corporation | $39,477.51 | 2019-2025 | |
| Genentech USA, INC. | $33,310.34 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Vabysmo |
| Horizon Therapeutics Plc | $21,585.54 | 2021-2023 | Uplizna |
| E.R. Squibb & Sons, L.L.C. | $19,789.36 | 2021-2025 | |
| Emd Serono, INC. | $8,662.72 | 2022-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $8,329.67 | 2019-2025 | Kesimpta |
| Tg Therapeutics, INC. | $6,287.05 | 2021-2025 | Briumvi |
| Genentech, INC. | $2,762.92 | 2020-2025 | Ocrevus |
| Biogen, INC. | $2,524.65 | 2020-2025 | Tysabri, Vumerity, Plegridy |
| Alexion Pharmaceuticals, INC. | $1,823.94 | 2022-2025 | Ultomiris, Soliris |
| Amgen INC. | $500.49 | 2024-2025 | Uplizna |
| Ani Pharmaceuticals, INC. | $202.50 | 2024-2025 | Purified Cortrophin Gel |
| Axonics, INC. | $146.01 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $46.05 | 2024-2025 | Tascenso Odt, Bafiertam |
| Banner Life Sciences, LLC | $38.50 | 2022 | |
| Janssen Pharmaceuticals, INC | $25.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Flavia Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.